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Manganese-containing Prussian blue nanoparticles 
for imaging of pediatric brain tumors
Abstract: Pediatric brain tumors (PBTs) are a leading cause of death in children. For an 
improved prognosis in patients with PBTs, there is a critical need to develop molecularly-
specific imaging agents to monitor disease progression and response to treatment. In this 
paper, we describe manganese-containing Prussian blue nanoparticles as agents for molecular 
magnetic resonance imaging (MRI) and fluorescence-based imaging of PBTs. Our core-shell 
nanoparticles consist of a core lattice structure that incorporates and retains paramagnetic Mn2+ 
ions, and generates MRI contrast (both negative and positive). The biofunctionalized shell is 
comprised of fluorescent avidin, which serves the dual purpose of enabling fluorescence imaging 
and functioning as a platform for the attachment of biotinylated ligands that target PBTs. The 
surfaces of our nanoparticles are modified with biotinylated antibodies targeting neuron-glial 
antigen 2 or biotinylated transferrin. Both neuron-glial antigen 2 and the transferrin receptor are 
protein markers overexpressed in PBTs. We describe the synthesis, biofunctionalization, and 
characterization of these multimodal nanoparticles. Further, we demonstrate the MRI and 
fluorescence imaging capabilities of manganese-containing Prussian blue nanoparticles in 
vitro. Finally, we demonstrate the potential of these nanoparticles as PBT imaging agents by 
measuring their organ and brain biodistribution in an orthotopic mouse model of PBTs using 
ex vivo fluorescence imaging.
Keywords: Prussian blue, nanoparticles, imaging, pediatric brain tumors, fluorescence, magnetic 
resonance imaging, manganese, multimodal
Introduction
Pediatric brain tumors (PBTs) are the most prevalent type of solid tumor in children 
and one of the leading causes of cancer-related death in the pediatric age group.1,2 The 
prognosis for children with aggressive PBTs such as glioblastoma multiforme, medullo-
blastoma, and diffuse intrinsic pontine glioma is poor, with virtually no long-term 
survivors.3–5 The reasons for the poor success in improving patient survival can 
be attributed to a historical lack of knowledge of the underlying biology of aggressive 
PBTs, and the lack of molecularly-specific imaging modalities to monitor disease 
progression and evaluate the response to treatment.6 
Over the past decade, technological progress made in the field of molecular biol-
ogy coupled with increased access to tissue samples from PBT patients (obtained via 
biopsy and/or autopsy) and the development of relevant animal models have improved 
our understanding of the underlying molecular biology of PBTs.3,6 However, thus 
far, there are no clinically approved, molecularly-specific imaging agents for PBTs, 
which can be primarily attributed to the challenges of working in the brain and cen-
tral nervous system, including crossing the blood–brain barrier and penetrating the 
brain parenchyma. In this paper, we describe a manganese-containing Prussian blue 
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(MnPB) nanoparticle for multimodal molecular magnetic 
resonance imaging (MRI) and fluorescence-based imaging 
of PBTs. 
Our rationale for pursuing nanoparticles is that they 
offer unique advantages that can be harnessed for molecular 
imaging of PBTs,7 including: small sizes (~10–200 nm) 
that enable the nanoparticles to easily penetrate body bar-
riers and extravasate across the leaky tumor vasculature of 
PBTs (via the enhanced permeability and retention effect, 
on account of the abnormal molecular and fluid transport 
dynamics of these tumors);8–10 high surface area-to-volume 
ratios that enable attachment of PBT-targeting ligands with 
high density; and the ability to be visualized via imag-
ing modalities such as MRI or fluorescence.11–14 There 
are numerous examples in the literature of nanoparticles 
being used for the imaging and treatment of a variety of 
cancers, including gold nanoparticles/nanorods/nanoshells, 
iron oxide nanoparticles, carbon nanotubes, dendrimers, 
polymer-based nanoparticles, and quantum dots.15–18 While a 
few of these nanoparticles are currently undergoing clinical 
evaluation,7,19–23 their use for molecular imaging of PBTs 
has been limited, thereby representing an opportunity for 
the field of nanomedicine. 
To generate nanoparticles suitable for imaging PBTs, 
we have synthesized MnPB nanoparticles with a core-shell 
design (Figure 1A). The Prussian blue nanoparticle core 
(iron [III] hexacyanoferrate [II]) has a permeable lattice 
structure and the ability to incorporate and retain metal 
ions for charge balance (Figure 1B). On account of this 
metal-binding ability, Prussian blue, a material approved by 
the US Food and Drug Administration and sold as Radio-
gardase™ (Heyltex Corporation, Katy, TX, USA),24 has 
been used by first responders in the event of a radiological 
emergency to sequester and promptly eliminate radioactive 
isotopes of cesium and thallium from the body.25,26 For the 
purpose of MRI, we can harness this metal-binding abil-
ity of Prussian blue to sequester paramagnetic Mn2+ ions 
within its lattice, thereby generating MRI contrast. We 
use manganese ions in the nanoparticles to mitigate safety 
concerns associated with gadolinium ions (Gd3+, typically 
used in commercial contrast agents) that have been linked 
to nephrogenic systemic fibrosis in patients with impaired 
renal function.27–30 
The Prussian blue nanoparticle core is coated with fluo-
rescently labeled avidin as previously described.31 The avidin 
coating biofunctionalizes the nanoparticle and serves as 
a platform for attaching biotinylated ligands for tumor 
targeting.32,33 The fluorescent avidin enables fluorescence 
imaging and detection of our nanoparticles. Our reason for 
selecting MRI and fluorescence as the molecular imaging 
modalities is on account of their complementary features. 
MRI offers superior spatial resolution and limitless penetra-
tion depths, while fluorescence imaging can be used to image 
phenomena with up to picomolar sensitivity.34 Further, MRI 
is the standard imaging modality for diagnosis and follow-up 
of PBTs,35 while fluorescence can be used to sensitively 
outline tumor margins, which is important when planning 
surgical resection of PBTs.36 To confer PBT molecular 
targeting capabilities, we utilize two different biotinylated 
ligands attached to the avidin-coated nanoparticles: a bioti-
nylated antibody targeting neuron-glial antigen 2, which is 
a cell surface chondroitin sulfate proteoglycan that has been 
observed to be overexpressed in numerous PBTs, includ-
ing glioblastoma multiforme and diffuse intrinsic pontine 
gliomas;37–39 and biotinylated transferrin, a glycoprotein that 
has been shown to specifically target a variety of tumors, 
Fe  
Fe Mn2+
K+
Manganese-containing Prussian blue
(MRI contrast agent)  
Fluorescent avidin
(fluorescence imaging)
Biotinylated PBT-
targeting ligand
(ANG2 or transferrin)
 
 
   
A
B
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II
Figure 1 Manganese-containing Prussian blue nanoparticles for imaging of PBTs.
Notes: (A) schematic representation of manganese-containing Prussian blue 
nanoparticles comprised of an inorganic core that provides MrI contrast and a 
biofunctionalized shell consisting of fluorescently-labeled avidin and biotinylated 
PBT-targeting ligands. (B) schematic representation of the Prussian blue lattice (ball 
and stick) containing interstitial Mn2+ and K+ ions. 
Abbreviations: aNg2, anti-neuron-glial antigen 2; MrI, magnetic resonance imaging; 
PBT, pedi atric brain tumor.
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including PBTs, and to assist various cargo in crossing the 
blood–brain barrier.40–42
Here we describe the synthesis, biofunctionalization, 
and characterization of the MnPB nanoparticles. We also 
evaluate the suitability of these nanoparticles for MRI and 
fluorescence-based imaging of PBTs in vitro using cells 
derived from brain tumors of a genetically engineered mouse 
model of PBT. Finally, we evaluate the imaging capabili-
ties of our nanoparticles by studying their organ and brain 
biodistribution in an orthotopic mouse model of PBT using 
ex vivo fluorescence imaging.
Materials and methods
Materials 
All synthetic procedures were conducted using ultrapure 
water obtained from a Milli-Q system (Millipore Corpora-
tion, Billerica, MA, USA) with resistivity 18 MΩ cm. All 
chemicals and reagents were purchased from Fisher-Acros 
(Thermo Fisher Scientific, Waltham, MA, USA) or Sigma-
Aldrich (St Louis, MO, USA), and used as supplied.
synthesis of MnPB nanoparticles 
Synthesis of the MnPB nanoparticles was carried out at ambi-
ent temperature by addition of a solution containing 0.0049 g 
FeCl
2
⋅4H
2
O (2.5×10-2 mmol) in 5 mL of Milli-Q water to a 
solution containing 0.0049 g MnCl
2
⋅4H
2
O (2.5×10-2 mmol) 
in 10 mL of Milli-Q water with vigorous stirring. This step 
was followed by immediate addition of a solution contain-
ing 0.0092 g of K
3
Fe(CN)
6
 (2.8×10-2 mmol) in 5 mL of  Milli-Q 
water. After stirring for a further 15 minutes, the resulting 
nanoparticle precipitate was collected by centrifuging, rinsed 
with copious amounts of Milli-Q water, and redispersed in 
Milli-Q water. Energy-dispersive X-ray spectroscopy of the 
blue powder obtained using the synthesis scheme yielded the 
formula: K
0.6
Mn
0.7
FeIII
4
[FeII(CN)
6
]
3.5
·3H
2
O. 
Physical characterization  
of MnPB nanoparticles
Transmission electron microscopy (TEM) of the MnPB 
nanoparticles was performed using a JEM-2100 FEG high-
resolution instrument (JEOL, Ltd, Tokyo, Japan) at 200 kV. 
Energy-dispersive X-ray spectroscopy was performed using 
an Inca 250 (Oxford Instruments, Abingdon, UK) coupled 
to the high-resolution TEM. Three scans of different parts 
of the MnPB sample were performed and averaged to obtain 
the relative percentages of iron, potassium, and manganese 
(Supplementary materials). X-ray diffraction patterns of the 
MnPB nanoparticles were measured on a D8 Advance powder 
diffractometer using CuKα radiation, and Topas software 
(Bruker AXS GmbH, Karlsruhe, Germany) was utilized for peak 
fitting via a fundamental parameters approach. Fourier trans-
form infrared (FTIR) spectra of the MnPB nanoparticles were 
recorded on an FTIR spectrometer (Thermo Nicolet Nexus 670, 
Thermo Fisher Scientific) using MnPB nanoparticle powders 
pressed against a ZnSe-attenuated total reflectance anvil.
Measurements of magnetic resonance 
relaxation times and data analysis  
of MnPB nanoparticles
All magnetic resonance measurements were performed 
in a horizontal 3 T clinical magnet (GE Healthcare, Little 
Chalfont, UK). The sample-containing phantom was placed 
adjacent to a block containing 2% agar (150 cm3) and secured 
at the center of an eight-channel HD brain coil (GE Health-
care). The MRI scanner was interfaced with the built-in 
GE Healthcare software. The magnetic resonance data 
were analyzed using ImageJ (National Institutes of Health, 
Bethesda, MD, USA). For each sample, the signal intensity 
of the acquired images was averaged over the area of the 
sample. The magnetic resonance images for MnPB nanopar-
ticles were acquired using clinical GE Healthcare sequences 
(T1 Cube, echo train 24; repetition time 600 msec; echo 
time 11.0 msec for T1-weighted, initial flip angle 120° and 
minimum flip angle 25°; and T2 Cube, echo train 100; repeti-
tion time 2,500 msec; echo time 79.6 msec for T2-weighted). 
The concentrations of Prussian blue and MnPB measured 
were 8.500, 4.250, 2.120, 1.062, 0.531, 0.265, 0.132, 0.066, 
0.033, 0.016, 0.008, and 0.004 mg/mL.
coating MnPB nanoparticles  
with fluorescent avidin
A 0.9 mL suspension of MnPB in Milli-Q water (180 µg/mL) 
and 0.1 mL of filtered Alexa Fluor 488-labeled avidin solution 
(A488, 1 mg/mL; Life Technologies, Carlsbad, CA, USA) or 
Avidin-Texas Red (ATxRd, 1 mg/mL; Life Technologies) 
were mixed by vortexing. The mixture was protected from 
light and contacted on an orbital shaker for at least 3 hours 
at 4°C. After contacting MnPB with fluorescent avidin, the 
unbound avidin was rinsed by centrifugation for 5 minutes 
at 20,000× g three times. In between each centrifugation, 
the supernatant was discarded and the particles (ie, MnPB-
A488 or MnPB-ATxRd) resuspended by brief sonication 
in 0.5 mL of Milli-Q water. After the last centrifugation, the 
particles were resuspended in Milli-Q water. 
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attaching biotinylated ligands  
onto avidin-coated MnPB
A 0.9 mL dispersion of avidin-coated MnPB nanoparticles in 
Milli-Q water (180 µg/mL) and 0.1 mL of filtered, biotiny-
lated anti-neuron-glial antigen 2 (ANG2; Millipore Corpora-
tion, Billerica, MA, USA), biotinylated eotaxin-3 antibody 
(AbC; PeproTech Inc) or biotinylated human transferrin 
(Rockland Immunochemicals, Inc., Gilbertsville, PA, USA) 
were mixed. The mixture was protected from light and con-
tacted on an orbital shaker for at least 3 hours at 4°C. After 
reaction, the unbound biotinylated ligands were removed 
by rinsing and the resulting biofunctionalized particles (ie, 
MnPB-A488-ANG2, MnPB-A488-AbC, or MnPB-ATxRd-
transferrin) were resuspended in Milli-Q water as described 
previously. The names and components of the nanoparticles 
used in this study are summarized in Table S1. 
Nanoparticle size, charge,  
and temporal stability
The sizes and zeta potentials of the suspensions of MnPB, 
avidin-coated MnPB, and biotinylated ligand-modified 
avidin-coated MnPB nanoparticles (10 µg/mL) were deter-
mined using a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK). The temporal stability of the nanoparticles 
was determined in Milli-Q water and Dulbecco’s Modified 
Eagle’s Medium (Life Technologies).
cells used for study
Adherent mouse brainstem glioma (BSG) D10 cells and 
nonadherent mouse neurospheres were derived from a 
genetically engineered mouse model of BSG as described 
previously.43 BSG D10 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium containing high glucose supple-
mented with 10% fetal bovine serum (Life Technologies) 
and 100 units/mL of penicillin plus 100 µg/mL of strepto-
mycin (Life Technologies). The cultures were maintained 
at 5% CO
2
 and 37°C. The mouse neurospheres were cultured 
in mouse Neurocult medium (Stem Cell Technologies, 
Vancouver, BC, Canada) supplemented with 10% mouse cell 
proliferation supplement (Stem Cell Technologies), glutamine, 
penicillin-streptomycin, heparin 2 µg/mL, recombinant 
mouse epidermal growth factor 20 ng/mL, and recombinant 
mouse fibroblast growth factor 10 ng/mL.
Molecular MrI-based detection  
of PBT cells
BSG D10 cells were grown in T75 flasks until ~80% conflu-
ence. The cells were blocked with 1% bovine serum albumin 
before addition of the nanoparticles. After the blocking step, 
the cells were incubated with MnPB-A488, MnPB-A488-
AbC, or MnPB-A488-ANG2 for a further hour. The cells 
were rinsed three times with 10 mL of phosphate-buffered 
saline to remove any nonspecifically bound nanopar-
ticles, trypsinized, and collected in a microcentrifuge tube 
at 2,100 rpm for 5 minutes. Finally, the cells were fixed 
with 10% formaldehyde in neutral buffer. After discarding 
the supernatant, each cell pellet was redispersed in 200 µL 
of Milli-Q water and pipetted into individual microcentri-
fuge tubes. A solution of 0.2 mL agarose (1%) was added to 
each tube and the tube contents were mixed thoroughly. The 
phantom comprised of sample-containing microcentrifuge 
tubes was placed next to a 2% solid agar block (150 cm3), 
secured, and measured as described previously. For each of 
the sequences, images were acquired at the identical coro-
nal 0.5 mm thick slice, positioned at mid-height of the tubes. 
A T1 spin echo sequence was used for T1-weighted images 
(repetition time 650 msec; echo time 11 msec; echo train 1; 
matrix size 320×256, field of view 10×10 cm2, flip angle 90°). 
T2-weighted images were acquired with a T2 fast relaxation 
fast spin echo sequence (repetition time 3,000 msec; echo 
time 101 msec; echo train 28; matrix size 384×288, field of 
view 10×10 cm2). For easier reading, the original gray scale 
images were converted into a color scale image. Normalized 
intensity was derived after subtracting the signal contribution 
from the agarose solution.
Fluorescence-based detection  
of PBT cells
BSG D10 cells were seeded on poly-L-lysine and laminin-coated 
chamber slides and grown under the culture conditions 
specified above. The cells were rinsed with phosphate-
buffered saline, fixed in 10% formaldehyde in neutral 
buffer solution for 15 minutes, and permeabilized in 0.1% 
Triton X-100 for a further 10 minutes. The cells were 
then blocked in 1% bovine serum albumin for one hour, 
followed by incubation with MnPB-A488, MnPB-A488-
AbC, or MnPB-A488-ANG2 nanoparticles for one addi-
tional hour. The cells were then rinsed three times with 
phosphate-buffered saline and immunostained for GFAP 
using anti-GFAP antibody (Abcam, Cambridge, UK) and 
Alexa-647-labeled secondary antibody (Life Technolo-
gies). For visualizing nuclei, the cells were briefly stained 
with 4′,6-diamidino-2-phenylindole (Life Technologies) and 
imaged using a laser scanning confocal microscope (Zeiss, 
Oberkochen, Germany) and ZEN 2009 software. Flow 
cytometry analysis of MnPB-A488, MnPB-A488-AbC, and 
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MnPB-A488-ANG2  nanoparticle specificity for BSG 
D10 was performed as described previously.26
Biodistribution of nanoparticles  
in a mouse model of PBT
The mouse studies were conducted in accordance with the 
protocols approved by the Children’s National Medical 
Center’s Institutional Animal Care and Use Committee 
(292-12-05, March 2013, and 01335, March 2014). The 
orthotopic mouse model of PBT was developed by inject-
ing 2-day-old BALB/c mice (The Jackson Laboratory, 
Bar Harbor, ME, USA) with neurospheres derived from a 
genetically engineered mouse model of BSG.43 The injected 
mice developed PBTs by 21 days post-injection. To  evaluate 
the brain and organ biodistribution of the nanoparticles, 
we injected MnPB-ATxRd-transferrin into the tail veins of 
mice with PBT. As controls, we utilized PBT mice that did 
not undergo nanoparticle injections. The mice were humanely 
euthanized at various time points (one, 3, 6, and 24 hours 
post-injection; controls were sacrificed at 3 hours) using car-
bon dioxide and cervical dislocation in accordance with the 
approved protocol. Organs, including the brain, liver, kidney, 
spleen, and heart, were extracted from the experimental and 
control mice, and fixed using 10% formaldehyde in neutral 
buffer. The fluorescence intensities of the various organs 
were measured using an IVIS Spectrum preclinical in vivo 
imaging system (PerkinElmer, Boston, MA, USA). Mouse 
brains that had a positive fluorescence signal were fixed 
in 10% formaldehyde in neutral buffer. Sagittal sections of 
the brains were stained with hematoxylin and eosin to detect 
the presence of tumor (hypercellularity).
statistical analysis
The mean ± standard deviation value for each group is pre-
sented in this study. Statistical significance between groups 
was analyzed using Student’s t-tests and one-way analysis 
of variance. A P-value 0.05 was considered to be statisti-
cally significant.
Results
synthesis and characterization  
of MnPB nanoparticles
The MnPB nanoparticles were prepared using a single-pot, 
aqueous phase synthesis by addition of iron (II) chloride to 
a mixture containing manganese chloride and potassium 
hexacyanoferrate (III). The resulting MnPB nanoparticles 
had a mean size of 33±7 nm, measured using high-resolution 
TEM (Figures 2A and S1), and the nanoparticle lattice 
 parameters corresponded to Prussian blue measured by 
selected area electron diffraction patterns (Figure S2). FTIR 
spectral measurements of the MnPB nanoparticles yielded a 
broad band at 2,070 cm-1, corresponding to the FeII–CN–FeIII 
cyanide stretch energy that was also obtained in the spectrum 
of Prussian blue (without manganese; Figure 2B). The FTIR 
spectrum for MnPB did not display a band at 2,149 cm-1 char-
acteristic of MnII–NC–FeIII.44
We determined the chemical composition of the MnPB 
nanoparticles using energy-dispersive X-ray spectroscopy and 
elemental analysis (Figure S3 and Table S2). These analyses 
derived the formula K
0.6
Mn
0.7
FeIII
4
[FeII(CN)
6
]
3.5
·3 H
2
O for 
MnPB with an average of 0.7 atoms of manganese per unit 
cell. X-ray diffraction studies of MnPB and Prussian blue 
nanoparticle powders yielded several groups of peaks that 
corresponded to Prussian blue lattices (space group Fm-3m; 
No. 225), confirming the presence of a single phase in both types 
of nanoparticle constituted by Prussian blue. No mixed phase 
peaks were detected, suggesting that both MnPB and Prussian 
blue were made up of the Prussian blue lattice (Figure S4).
We serially diluted Prussian blue and MnPB nano-
particles to determine their longitudinal and transverse 
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Figure 2 Properties of the MnPB nanoparticles.
Notes: (A) representative transmission electron microscopy image of MnPB 
nanoparticles. (B) Fourier transform infrared spectra of Prussian blue without 
interstitial manganese (solid line) and MnPB (dashed line) in the cyanide stretching 
region (1,900 cm-1 to 2,200 cm-1). 
Abbreviation: MnPB, manganese-containing Prussian blue.
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relaxivities (r
1
 and r
2
 values, respectively) at a magnetic 
field strength of 3 T (Figures 3 and S5). Relaxivity mea-
surements with MnPB yielded an r
1
 value of 15.8 mM-1 s-1 
and an r
2
 value of 143 mM-1 s-1. Similar measurements car-
ried out with Prussian blue (without manganese) yielded 
an r
1
 value of 7.9 mM-1 s-1 and an r
2
 value of 14.4 mM-1 s-1. 
The r
1
 and r
2
 values for MnPB and Prussian blue are shown 
in Table 1.
sizing, stability, and reproducibility  
of biofunctionalized MnPB nanoparticles
Our syntheses consistently yielded nanoparticles with a 
~5%–10% variation in size between batches. Using light 
scattering techniques, we observed a change in the zeta 
potential (from -38 mV to -15 mV to -24 mV) and an 
increase in the hydrodynamic diameter of the MnPB nano-
particles (from 126±25 nm to 159±30 nm to 240±48 nm; 
Figure 4A) with the addition of the individual components 
of the biofunctional shell, ie, from MnPB (without modi-
fications) to MnPB-A488 (MnPB coated with A488) and 
MnPB-A488-ANG2 (MnPB-A488 coated with biotinylated 
antibody ANG2). The resulting biofunctionalized nanopar-
ticles were stable in both water and Dulbecco’s Modified 
Eagle’s Medium (Figure 4B) for 4 days (110 hours) 
after synthesis. The error bars in Figure 4B represent 
the instrument error in measuring the hydrodynamic dia-
meters of the nanoparticles. We evaluated the safety of the 
MnPB-A488-ANG2  nanoparticles as a molecular imaging 
agent by conducting cytotoxicity studies. These studies indi-
cated negligible cytotoxicity at nanoparticle concentrations 
of 1.25×10-7 mg/cell at 24 and 48 hours (Figure S6). 
In vitro molecular MrI-based  
detection of PBT cells
To evaluate MnPB-A488-ANG2 nanoparticles as molecu-
larly-targeted MRI agents for detecting PBT cells, we con-
tacted BSG D10 cells with MnPB-A488-ANG2 (n=6), with 
MnPB-A488-AbC (n=3), and with MnPB-A488 (n=3); we 
then scanned the sample-containing phantoms, and obtained 
T1-weighted and T2-weighted images (Figure 5). The MnPB-
A488-ANG2 nanoparticles bound to the BSG D10 cells and 
generated hyperintensity (augmentation of the signal) in 
Table 1 Magnetic resonance measurements of relaxivity of MnPB 
nanoparticles
Contrast  
agent
Chemical composition Relaxivity (mM-1 s-1)
r1 r2
MnPB K0.6Mn0.7Fe
III
4[Fe
II(cN)6]3.5⋅3h2O 15.8 143.0
Prussian blue K2.8Fe
III
4[Fe
II(cN)6]3.7⋅2h2O 7.9 14.4
Note: Magnetic resonance measurements of relaxivity were performed at 
127 mhz (3 T). 
Abbreviation: MnPB, manganese-containing Prussian blue.
 
Prussian blue  
Nanoparticle concentration
MnPB  
Prussian blue  
MnPB  
T1W 
T2W
Figure 3 T1W and T2W magnetic resonance images of Prussian blue and MnPB 
at 3 T. 
Abbreviations: T1W, T1-weighted; T2W, T2-weighted; MnPB, manganese-containing 
Prussian blue.
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Figure 4 size and stability of biofunctionalized MnPB nanoparticles.
Notes: (A) size distribution of MnPB-a488-aNg2 after each functionalization step. 
hydrodynamic size distributions of the MnPB nanoparticles, MnPB nanoparticles 
coated with avidin-Alexa Fluor 488 (MnPB-A488), and MnPB-A488 modified with 
biotinylated anti-neuron-glial antigen 2 (MnPB-a488-aNg2), respectively. (B) Tem-
poral stability of MnPB nanoparticles and MnPB-a488-aNg2 in Milli-Q water and 
Dulbecco’s Modified Eagle’s Medium for up to 4 days post synthesis. 
Abbreviations: MnPB, manganese-containing Prussian blue; a488, avidin-alexa 
Fluor 488; aNg2, anti-neuron-glial antigen 2 antibody; DMeM, Dulbecco’s Modified 
eagle’s Medium.
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the T1-weighted images and hypointensity (attenuation of 
the signal) in the T2-weighted images (Figure 5A). Control 
(MnPB-A488-AbC [control antibody] and MnPB-A488 [no 
antibody]) nanoparticles exhibited negligible binding to BSG 
D10 and the observed changes in magnetic resonance signal 
intensity were modest (Figure 5A). Quantitative analysis 
of the T1-weighted images showed that the MnPB-A488-
ANG2 nanoparticles bound to BSG D10 and were distinctly 
detected (signal intensity of 94 au). The controls (MnPB- 
A488-AbC and MnPB-A488) showed background contrast 
levels, ie, a signal intensity of ~10 au (Figure 5B). Signal 
intensity quantification of the T2-weighted images confirmed 
that MnPB-A488-ANG2 nanoparticles specifically bound 
to BSG D10 as it generated hypointensity (signal intensity 
of 41 au). The controls (MnPB-A488-AbC and MnPB-A488) 
did not display significant attenuation of the signal (107 and 75, 
respectively; Figure 5B). These results demonstrated the feasi-
bility of detecting PBT cells using our biofunctionalized MnPB 
nanoparticles in both T1-weighted and T2-weighted images.
In vitro fluorescence-based  
detection of PBT cells 
To investigate our nanoparticles as fluorescence imaging 
agents, we added fixed amounts of MnPB-A488-ANG2 (con-
taining ANG2 antibody), MnPB-A488-AbC (with control 
antibody AbC), and MnPB-A488 (no antibody) to BSG 
D10 cells. Confocal fluorescence microscopy demonstrated 
that the MnPB-A488-ANG2 specifically targeted BSG 
D10 cells (Figure 6). Control (MnPB-A488-AbC and MnPB-
A488) nanoparticles showed negligible binding to BSG 
D10 (negligible green fluorescence; Figure 6A and 6B). 
We quantitatively measured the binding of MnPB-A488-
ANG2 to BSG D10 using flow cytometry. We separately added 
MnPB-A488-ANG2 and controls (MnPB-A488-AbC and 
MnPB-A488) to cultures of BSG D10 and measured the dis-
tribution of the cell populations that were fluorescently labeled 
(denoted as Alexa Fluor 488-positive; Figures 7A and S7). 
The MnPB-A488-ANG2 nanoparticles specifically bound 
to the BSG D10 cells (81%±4% Alexa Fluor 488-positive; 
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Figure 5 Molecular MrI-based detection of PBT cells using biofunctionalized 
Prussian blue nanoparticles. (A) T1-weighted and T2-weighted contrast enhancement 
in phantoms comprised of a fixed number of BSG D10 treated with MnPB-A488-
aNg2 (n=6), MnPB-a488-abc (n=3), or MnPB-a488 (no antibody, triplicate). (B) 
Normalized fluorescence signal intensity (au) for BSG D10 treated with ANG2, 
AbC, and no antibody-modified MnPB-A488. **P0.05. 
Abbreviations: MnPB, manganese-containing Prussian blue; a488, avidin-alexa 
Fluor 488; aNg2, anti-neuron-glial antigen 2; abc, eotaxin antibody; Bsg, brainstem 
glioma; T1W, T1-weighted; T2W, T2-weighted; PBT, pediatric brain tumor; au, 
arbitrary units; ab, antibody; MrI, magnetic resonance imaging.
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Figure 6 Fluorescence-based detection of PBT cells using biofunctionalized Prussian blue nanoparticles.
Notes: Fluorescent image of Bsg D10 treated with control nanoparticles, ie, (A) MnPB-a488 and (B) MnPB-a488-abc, and experimental nanoparticles, ie, (C) MnPB-a488-
ANG2. The green fluorescence comes from A488 on the constructs. Scale bars represent 20 µm. 
Abbreviations: Bsg, brainstem glioma; MnPB, manganese-containing Prussian blue; a488, avidin-alexa Fluor 488; aNg2, anti-neuron-glial antigen 2; abc, eotaxin antibody; 
PBT, pediatric brain tumor.
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Figure 7B) compared with MnPB-A488-AbC (23%±2% 
Alexa Fluor 488-positive; Figure 7B) and MnPB-A488 
(22%±3% Alexa Fluor 488-positive; Figure 7B) where the 
nanoparticles showed background levels of binding to BSG 
D10 cells. Taken together, these results demonstrated the ability 
of our nanoparticles (with antibody ANG2) to molecularly tar-
get BSG D10 cells effectively using fluorescence imaging.
ex vivo nanoparticle  
biodistribution studies
In order to investigate the feasibility of our nanoparticles 
as imaging agents in vivo, we conducted preliminary fluo-
rescence biodistribution studies. Mice with PBTs were 
intravenously administered MnPB-ATxRd-transferrin 
nanoparticles. We made two changes to the nanoparticle 
design: we chose transferrin as the targeting ligand on the 
nanoparticles since our mice with PBTs were observed to 
overexpress the transferrin receptor compared with neuron-
glial antigen 2 (from our unpublished proteomic analysis 
of mice PBTs); and we selected Texas Red as the imaging 
fluorophore because tissue penetration depths are increased 
and tissue autofluorescence is decreased as the selected 
imaging fluorophore wavelengths are red-shifted toward near 
infrared wavelengths. Following intravenous injection, the 
mice organs, ie, brain, liver, kidney, spleen and heart, were 
harvested at different time points (between one and 24 hours) 
and their fluorescence measured. 
Fluorescence measurements of the brains of the mice 
detected the nanoparticles in the brain between one hour 
and 3 hours, with the fluorescent signal reaching a maxi-
mum at one hour (Figure 8A). Little to no fluorescence 
was detected after 3 hours and in the control mouse brain 
(without nanoparticle injection). Fluorescence organ biodis-
tribution measurements showed that the nanoparticles were 
cleared via the liver, kidney, and spleen (Figure 8B and 8C). 
Mouse brains that were positive for fluorescent signal were 
analyzed by histology. Sagittal sections of the brain stained 
by hematoxylin and eosin revealed a hypercellular region 
located within the fluorescently active brain segment local-
ized in the ventricular and periventricular regions of the 
mouse brain (Figure 9). These results indicated the feasibil-
ity of utilizing our nanoparticles for fluorescence imaging 
of PBTs in vivo. 
Discussion
Here we have described the synthesis of novel MnPB 
nanoparticles by utilizing the cation-incorporating prop-
erty (for charge neutrality) of Prussian blue nanoparticles. 
Comprehensive physical and chemical characterization 
(Figures 2 and S1–S4) of these nanoparticles using TEM, 
energy-dispersive X-ray spectroscopy, powder X-ray diffrac-
tion, and FTIR confirmed that they have a structure virtually 
identical to that of Prussian blue nanoparticles, indicating that 
the Mn2+ ions were not modifying the Prussian blue lattice 
structure and likely occupying the lattice tetragonal sites 
(interstitial vacancies). MnPB nanoparticles possess MRI 
Figure 7 Flow cytometric analysis of the specificity of biofunctionalized MnPB 
nanoparticles for PBT cells.
Notes: (A) representative histograms of cell count plotted against alexa Fluor 
488 detection levels for Bsg D10 cells treated with MnPB-a488 (no antibody, red 
line), MnPB-a488-abc (blue line), and MnPB-a488-aNg2 (black line), and stained 
with 7-aaD. (B) Percentage Alexa Fluor 488-positive cells (fluorescence intensity 
cutoff  50) cells for Bsg D10 treated with MnPB-a488-aNg2, MnPB-a488-abc, 
or MnPB-A488. **P0.05. 
Abbreviations: Bsg, brainstem glioma; 7-aaD, 7-aminoactinomycin D; MnPB, 
manganese-containing Prussian blue; a488, avidin-alexa Fluor 488; aNg2, anti-
neuron-glial antigen 2; PBT, pediatric brain tumor; au, arbitrary units.
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contrast-enhancing capabilities (both negative and positive), 
which was confirmed by generation of positive contrast on 
a T1-weighted image sequence and negative contrast on 
a T2-weighted image sequence at 3 T (Figures 3 and S4, 
Table 1). Compared with Gd3+-containing commercial con-
trast agents, which are typically used solely as positive con-
trast agents, the magnetic measurement data established the 
efficiency of the MnPB nanoparticles as MRI contrast agents 
useful in both T1-weighted and T2-weighted sequences, 
thus confirming MnPB nanoparticles as versatile contrast 
agents in new imaging applications involving  combinations 
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Figure 8 Ex vivo fluorescence imaging of biodistribution of the nanoparticles in an 
orthotopic mouse model of PBT.
Notes: (A) Fluorescent signal observed in the brains of four separate mice with PBT 
(1–24 hours) injected intravenously (via tail vein) with transferrin-coated Prussian blue 
nanoparticles (MnPB-aTxrd-Tf). a control mouse with PBT was not injected with 
nanoparticles. (B) Representative ex vivo fluorescence imaging of organ biodistribution 
of the nanoparticles at 3 hours post-injection. (C) histograms quantifying the observed 
fluorescence biodistribution of the nanoparticles 3 hours post-injection. ROIs for 
intensity measurements are indicated by white dashed lines in (B). 
Abbreviations: PBT, pediatric brain tumor; MnPB, manganese-containing Prussian 
blue; aTxrd, Texas red-labeled avidin; Tf, transferrin; rOI, region of interest; 
au, arbitrary units.
A
C D
B
Figure 9 Histological analysis of fluorescence-positive regions of mice brains with 
PBTs.
Notes: (A) sagittal slice of mouse brain stained with hematoxylin and eosin. 
(B) Inset showing a fluorescence image of the brain, with arrow indicating the viewing 
direction of the sagittal section in (A). (C, D) Progressive zooms of the hematoxylin 
and eosin-stained sagittal brain sections containing a hypercellular ventricular and 
periventricular region within the fluorescence-positive region. 
Abbreviation: PBT, pediatric brain tumor.
of both T1-weighted and T2-weighted sequences. Prelimi-
nary studies confirm the feasibility of utilizing MnPB as 
MRI contrast agents in both T1-weighted and T2-weighted 
sequences (Figure S8).
The surface of the MnPB nanoparticles was negatively 
charged (zeta potential -38 mV), which electrostatically 
stabilized the nanoparticle suspension, thereby eliminating 
the need for stabilizing surfactants.45,46 To biofunctionalize 
the nanoparticles for molecular targeting of PBTs, the MnPB 
nanoparticles were first coated with a layer of fluorescent 
avidin (A488 or ATxRd). Avidin, which is a highly posi-
tively charged glycoprotein at physiological pH (isoelectric 
point ~10.5), was coated on the surface of the negatively 
charged MnPB nanoparticles using electrostatic self-
assembly.15,17 The surfaces of the fluorescent avidin-coated 
MnPB  nanoparticles were modified with the PBT-targeting 
or control ligands (ANG2, transferrin, or AbC) via an 
avidin- biotin interaction, which is one of the most robust, 
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 noncovalent interactions identified (K
d
 =10-15 M), and is 
capable of  sustaining extremes of temperature, pH, and 
harsh chemical conditions.15,33,47,48 The biofunctionalized 
nanoparticles demonstrated temporal stability (over 4 days), 
both in water and in Dulbecco’s Modified Eagle’s Medium 
(Figure 4), and negligible cytotoxicity (at concentrations 
1.25×10-7 mg/cell; Figure S6) to PBT cells (BSG D10), 
indicating their safety for use as molecular imaging agents. 
The nanoparticles were able to specifically detect PBT 
cells (BSG D10) using MRI in both T1-weighted and 
T2-weighted sequences by generating specific positive 
and negative contrast, respectively, relative to the controls 
that exhibited background contrast (Figure 5). The nano-
particles also demonstrated specific fluorescence-based 
detection of PBT cells (Figures 6 and 7, and S7). These 
results validated the utility of our nanoparticles as multimodal 
imaging agents for PBTs. 
Preliminary biodistribution studies using ex vivo fluores-
cence imaging in a mouse model of PBT indicated that the 
nanoparticles were cleared via the liver, kidney, and spleen 
(Figure 8). Longer circulation times and lower immunogenic-
ity of our nanoparticles for future in vivo imaging studies will 
require modifications of the current design, including coating 
of the nanoparticles with the “stealth” polymer, polyethylene 
glycol (PEGylation),18,49,50 which is currently being investi-
gated. Ex vivo brain fluorescence biodistribution studies also 
demonstrated that the fluorescent signal of our nanoparticles 
was detected in the brain between one hour and 3 hours. His-
tological analysis of the fluorescent region within the mouse 
brain confirmed the presence of a hypercellular region in the 
ventricular and periventricular regions overlapping the region 
of the brain exhibiting a fluorescent signal (Figure 9). The 
increased fluorescence signal in the brain was possibly due 
to an increased transient presence of our nanoparticles in the 
hypercellular region within the brain (Figure 9). For future in 
vivo imaging of PBTs, the design of our nanoparticles will be 
modified to incorporate ligands (by varying type of ligand, 
ligand surface density) that cross the blood–brain barrier, 
penetrate the brain parenchyma, and assist uptake within 
PBTs.51,52 These studies are currently in progress. 
Conclusion
In this paper, we describe the synthesis and characterization 
of novel, biofunctionalized MnPB nanoparticles for imaging 
PBTs. These nanoparticles exhibited fluorescence as well as 
superior and versatile MRI contrast enhancement  capabilities. 
We demonstrated these nanoparticles to be multimodal 
imaging agents using MRI and fluorescence-based  detection 
of PBT cells in vitro. Preliminary ex vivo fluorescence 
imaging provided a proof-of-concept demonstration of our 
 nanoparticles as imaging agents and suggests the potential of 
these nanoparticles as agents for multimodal and molecular 
imaging of PBTs in vivo.
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Table S1 Names and components of nanoparticles described in text
Construct name Core Fluorophore in avidin layer Targeting ligand
MnPB MnPB None None
MnPB-a488 MnPB alexa Fluor 488 None
MnPB-aTxrd MnPB Texas red None
MnPB-a488-aNg2 MnPB alexa Fluor 488 anti-neuron-glial antigen 2
MnPB-a488-abc MnPB alexa Fluor 488 eotaxin-3 antibody 
MnPB-aTxrd-Tf MnPB Texas red human transferrin 
Abbreviation: MnPB, manganese-containing Prussian blue particles.
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Figure S1 size of manganese-containing Prussian blue nanoparticles.
Notes: (A) Transmission electron micrograph of an oversized agglomerate consisting of over 500 nanoparticles (scale bar 1 µm) used for selected area electron diffraction. 
(B) histogram showing the size distribution of 198 nanoparticles with a mean nanoparticle size of 33±7 nm. The size analysis was performed with ImageJ software by manually 
measuring the size of the individual nanoparticles from the transmission electron microscopy images of well dispersed, individual nanoparticles.
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Figure S2 Selected area electron diffraction pattern of a manganese-containing Prussian blue nanoparticle with 200, 220, and 400 reflections identified as the lattice 
corresponding to Prussian blue.
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Figure S3 composition of manganese-containing Prussian blue nanoparticles.
Notes: (A) energy-dispersive X-ray spectrum corresponding to the region of interest shown in (B), which is a representative transmission electron micrograph of the 
nanoparticles. The purple line indicates the limits of a typical region of interest analyzed by energy-dispersive X-ray spectroscopy. The composition was derived by built-in 
software (Inca; Oxford Instruments, Abingdon, UK) from the attribution of the electronic energy profile for Fe, K, and Mn.
Table S2 summary of relative percentages of potassium, iron, and 
manganese from three distinct energy-dispersive X-ray spectroscopic 
scans of manganese-containing Prussian blue particles
Potassium (%) Iron (%) Manganese (%)
spectrum 1 9.03 79.86 7.86
spectrum 2 8.53 85.73 7.32
spectrum 3 8.77 84.05 8.87
16     18      20     22      24      26       35        40
2,000
4,000
6,000
8,000
10,000
12,000
14,000
 PB
 MnPB
C
o
u
n
ts
Diffraction angle 2θ (degrees)
Figure S4 room temperature X-ray diffractogram of a sample of MnPB and PB with 
peaks at around 17, 24, and 35 degrees, corresponding to the 200, 220, and 400 
diffraction planes, respectively.
Notes: X-ray diffraction from a sample of particles showed several groups of 
peaks corresponding to the 200, 220, and 400 diffraction planes at 17.43, 24.67, 
and 35.24 degrees, respectively, for MnPB and 17.51, 24.68, and 35.29 degrees, 
respectively, for PB. These diffraction peaks were indexed to Prussian blue 
lattices using the space group Fm-3m (No. 225) and confirmed the presence of 
one phase constituted by Prussian blue. Using the (400) reflections fitted to a 
gaussian function, the lattice parameters for each compound were calculated. 
We found the following lattice constants: MnPB (a =10.19 Å) and PB (a =10.17 Å). 
No peaks corresponding to a mixed phase (such as manganese) with different 
lattice parameters were detected, suggesting that both MnPB and PB are made up 
of the Prussian blue lattice.
Abbreviations: PB, Prussian blue particles without interstitial gadolinium; MnPB, 
manganese-containing Prussian blue.
Figure S5 Inverse of relaxation times (1/T1=r1 and 1/T2=r2) plotted against 
concentrations of the main paramagnetic ion.
Note: r1 and r2 values are derived from the linear fitting of these plots.
Abbreviations: PB, Prussian blue particles without interstitial gadolinium; MnPB, 
manganese-containing Prussian blue.
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Figure S6 cytotoxicity studies of biofunctionalized MnPB nanoparticles. Viability (survival percentage) of Bsg D10 coincubated with varying concentrations of MnPB-a488-
aNg2 determined by (A) Trevigen® XTT assay and (B) Trypan blue exclusion assay.
Notes: **P0.05. We seeded 10,000 and 50,000 Bsg D10 cells for the XTT and Trypan blue exclusion assays, respectively, before adding varying concentrations of MnPB-
a488-aNg2 to the cells (studies were performed in triplicate). The cells were coincubated with the nanoparticles for 48 hours at 37°c and 5% cO2. The cell viability assays 
indicated minimal cytotoxicity at nanoparticle concentrations lower than 1.25×10-7 mg/cell after 24 and 48 hours using both assays.
Abbreviations: Bsg, brainstem glioma; MnPB, manganese-containing Prussian blue; aNg2, anti-neuron-glial antigen 2.
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Figure S7 (Continued).
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Figure S7 Flow cytometric analysis of nanoparticle specificity for BSG D10 cells.
Notes: For clarity, the axes legends have been omitted. The side light scattering is displayed on the x-axis (abscissa) and the forward light scattering on the y-axis (ordinate). 
Flow cytometric analysis of the Bsg D10 treated with (A) MnPB-aV488, (B) MnPB-aV488-abc, and (C) MnPB-A488-ANG2 demonstrated specific targeting of BSG D10 
cells using the targeted MnPB-a488-aNg2 nanoparticles.
Abbreviations: Bsg, brainstem glioma; MnPB, manganese-containing Prussian blue; aNg2, anti-neuron-glial antigen 2.
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Figure S8 Magnetic resonance images of mouse brains injected ex vivo with two concentrations of MnPB and with saline (control).
Notes: Mouse brains preserved in 10% formaldehyde in neutral buffer were injected with 10 µl or 20 µl of a dispersion of 8.5 mg/ml MnPB or 20 µl of saline. The brains 
were superficially rinsed with Milli-Q water and embedded in 0.5% agarose prior to imaging. Magnetic resonance images were acquired using clinical GE Healthcare sequences 
(T1 FlaIr: echo train 7; repetition time 2,300 msec; echo time 24.4 msec; matrix size 512×224, field of view 16×16 cm2; and T2 FrFse: echo train 21; repetition time 3,500 
msec; echo time 104 msec; matrix size 20×224; field of view 16×16 cm2).
Abbreviation: MnPB, manganese-containing Prussian blue.
